This review considers trastuzumab's mechanism of action and its clinical value. As shown in Panel A, the four members of the HER family are HER1, HER2, HER3, and HER4. There are receptor-specific ...

Another possible mechanism of action is the preferential exertion of antibody- dependent cellular cytotoxicity on HER2-overexpressing cancer cells. [62] Trastuzumab contains an immunoglobulin G1 ...

The persistence of HER2 overexpression confirms that trastuzumab-mediated ADCC is a feasible mechanism of action for the drug. Trastuzumab plus docetaxel is an approved and well-tolerated ...

13 In ErbB2-positive xenograft models, lapatinib combined with trastuzumab resulted in stabilization of inactive ErbB2 receptor as a result of a mechanism of action attributed to lapatinib, followed ...

Trastuzumab, a humanized monoclonal antibody directed at the extracellular domain of HER2, is also active in the same group of patients with breast cancer. Proposed mechanisms of action of ...

In breast cancer, HER2-targeted therapy with trastuzumab has gained significant attention, owing to the dramatic response observed in a subset of HER2-positive patients. The mechanisms of action ...

Trastuzumab is a monoclonal antibody targeted against the human epidermal growth factor receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of invasive breast ...

Trastuzumab has changed the standard of care for MBC patients who overexpress the HER2-receptor protein. In heavily pretreated patients who overexpress HER2, trastuzumab produces objective ...

The efficacy of trastuzumab, both as a single agent ... Tremendous resources have been spent in efforts to elucidate the mechanisms of action, safety, optimal combination therapies and mechanisms ...

In general, trastuzumab therapy is well tolerated. The most common adverse events are infusion related -- primarily fever and chills -- and occur in approximately 40% of patients during the ...